ONC Share Price

Open 0.50 Change Price %
High 0.51 1 Day 0.00 0.00
Low 0.50 1 Week -0.06 -10.71
Close 0.50 1 Month 0.04 8.70
Volume 99512 1 Year 0.10 25.00
52 Week High 1.13
52 Week Low 0.19
ONC Important Levels
Resistance 2 0.51
Resistance 1 0.51
Pivot 0.50
Support 1 0.49
Support 2 0.49
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
SC 60.83 -0.44%
YRI 3.20 1.27%
PRE 0.64 0.00%
PRE 0.64 0.00%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
MNR 0.22 37.50%
MNR 0.22 37.50%
PWC 0.10 25.00%
PWC 0.10 25.00%
NKO 0.06 20.00%
NKO 0.06 20.00%
More..
TSE Canada Top Losers Stocks
HE 0.02 -50.00%
HE 0.02 -50.00%
GBV 0.46 -24.59%
IMP 0.07 -12.50%
IMP 0.07 -12.50%
IMP 0.07 -12.50%
CTU-A 0.19 -9.52%
BOY 0.44 -8.33%
BOY 0.44 -8.33%
BOY 0.44 -8.33%
More..

Oncolytics Biotech Inc (TSE: ONC)

ONC Technical Analysis 2
As on 20th Jul 2017 ONC Share Price closed @ 0.50 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.45 & Strong Sell for SHORT-TERM with Stoploss of 0.61 we also expect STOCK to react on Following IMPORTANT LEVELS.
ONC Target for July
1st Target up-side 0.63
2nd Target up-side 0.71
3rd Target up-side 0.79
1st Target down-side 0.41
2nd Target down-side 0.33
3rd Target down-side 0.25
ONC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oncolyticsbiotech.com
ONC Address
ONC
1167 Kensington Crescent NW
Suite 210
Calgary, AB T2N 1X7
Canada
Phone: 403-670-7377
Fax: 403-283-0858
ONC Latest News
Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of ...   PR Newswire (press release)   - 29th Jun 17
Oncolytics Biotech® Inc. Opens US Based Office in San Diego   PR Newswire (press release)   - 27th Jun 17
Oncolytics Biotech Prices Public Offering of Units   MarketWatch   - 24th May 17
Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies ...   Canada NewsWire (press release)   - 18th May 17
Oncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in ...   Canada NewsWire (press release)   - 08th May 17
Finally, Some Good News For Oncolytics   Seeking Alpha   - 03rd Apr 17
Media Advisory - Oncolytics Biotech® Inc. Announces Management Team Changes   PR Newswire (press release)   - 03rd Nov 16
Where Can Oncolytics Go After Dismal ASCO Results?   Seeking Alpha   - 20th May 16
Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II ...   PR Newswire (press release)   - 19th May 16
Oncolytics Biotech, Inc.: An Intro To These Next Few Crucial Weeks   Seeking Alpha   - 12th Feb 13
Interactive Technical Analysis Chart Oncolytics Biotech Inc ( ONC TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Oncolytics Biotech Inc
ONC Business Profile
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.